<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03717506</url>
  </required_header>
  <id_info>
    <org_study_id>GDC-268-001</org_study_id>
    <nct_id>NCT03717506</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 268 and Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gage Development Company, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gage Development Company, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the safety, tolerability, and therapeutic&#xD;
      equivalence of GDC 268 to Clindamycin Phosphate Topical Lotion, 1% and to compare the&#xD;
      efficacy of these two products to the GDC vehicle lotion (i.e., placebo) in the treatment of&#xD;
      acne vulgaris.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2018</start_date>
  <completion_date type="Actual">April 16, 2020</completion_date>
  <primary_completion_date type="Actual">February 17, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Percent Change in the Number of Inflamed Lesions</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent Change from Baseline to Week 12 in inflammatory lesion counts (Papules/Pustules).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Percent Change in the Non-inflammatory Lesion Counts</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent Change (i.e., reduction) from Baseline to Week 12 in non-inflammatory (open and closed comedones) lesion counts.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Subjects With a Clinical Response (IGA) of &quot;Success&quot; at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Investigator's Global Assessment, IGA. Overall severity of acne was assessed using a five-point scale from 0=Clear to 4=Severe. Subjects must have had an IGA score of 2 (mild), 3 (moderate), or 4 (severe) at Baseline. Success is defined as an IGA score at week 12 that is at least 2 grades less than the baseline assessment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Day 1 through Day 85</time_frame>
    <description>Adverse Events (AEs) will be assessed by the investigator and the incidence (severity and causality) of any local and systemic AEs will be reported by number and percentage.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1236</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Test product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GDC 268 Lotion applied topically as directed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clindamycin Phosphate Lotion, 1% applied topically as directed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>GDC Vehicle lotion applied topically as directed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC 268 Lotion</intervention_name>
    <description>GDC 268 is a topical lotion</description>
    <arm_group_label>Test product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin Phosphate Lotion 1%</intervention_name>
    <description>Clindamycin Phosphate Lotion is an FDA-approved drug product</description>
    <arm_group_label>Reference Product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GDC Vehicle Lotion</intervention_name>
    <description>GDC Vehicle Lotion contains 0.0% of active drug and is matched to the other two active test drugs</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or non-pregnant, non-lactating female, ≥12 and ≤40 years of age with a clinical&#xD;
             diagnosis of acne vulgaris.&#xD;
&#xD;
          -  Must have ≥ 25 but ≤ 100 non-inflammatory lesions (open and closed comedones) AND ≥ 20&#xD;
             but ≤ 70 inflammatory lesions (papules and pustules) AND ≤ 2 nodulocystic lesions&#xD;
             (nodules and cysts) on the face (e.g., forehead, nose, cheeks, chin, upper lip) at&#xD;
             Baseline.&#xD;
&#xD;
          -  Must be willing and able to refrain from use of all other topical products in the&#xD;
             treatment area, all acne medications other than test article, and all antibiotics&#xD;
             (other than test article) during the 12-week treatment period.&#xD;
&#xD;
          -  Women must be surgically sterile, or use an effective method of birth control with a&#xD;
             negative urine pregnancy test (UPT) at the Baseline Visit (Day 1).&#xD;
&#xD;
          -  In good general health and free of any other clinically significant disease state or&#xD;
             physical condition.&#xD;
&#xD;
          -  Subject has provided written informed consent / assent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is pregnant, breastfeeding, or is planning to become pregnant or breastfeed&#xD;
             during the study.&#xD;
&#xD;
          -  Subject has more than 2 facial nodular lesions; any nodules present will be documented&#xD;
             but not included in the inflammatory lesion count for analysis.&#xD;
&#xD;
          -  Subject has excessive facial hair (e.g., beards, sideburns, moustaches), facial&#xD;
             tattoos, or other facial attributes that would interfere with diagnosis or assessment&#xD;
             of acne vulgaris in the opinion of the investigator.&#xD;
&#xD;
          -  Subject is planning surgery during the study.&#xD;
&#xD;
          -  Subject has a history of hypersensitivity or allergy to clindamycin or lincomycin&#xD;
             and/or any of the ingredients in the test articles.&#xD;
&#xD;
        Other Eligibility Criteria not listed above will be reviewed for each prospective subject&#xD;
        by the study staff.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site 07</name>
      <address>
        <city>Fort Smith</city>
        <state>Arkansas</state>
        <zip>72916</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 22</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 25</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 33</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 30</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 44</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 36</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 45</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 41</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 35</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 38</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33145</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 37</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 26</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 42</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 01</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 10</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 09</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 05</name>
      <address>
        <city>Rolling Meadows</city>
        <state>Illinois</state>
        <zip>60008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 02</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 27</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 28</name>
      <address>
        <city>Clarkston</city>
        <state>Michigan</state>
        <zip>48346</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 24</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 49</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 06</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 32</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 19</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 17</name>
      <address>
        <city>Gresham</city>
        <state>Oregon</state>
        <zip>97030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 34</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 20</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 08</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 29</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 03</name>
      <address>
        <city>Murfreesboro</city>
        <state>Tennessee</state>
        <zip>37130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 04</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 43</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 22, 2018</study_first_submitted>
  <study_first_submitted_qc>October 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2018</study_first_posted>
  <results_first_submitted>April 9, 2021</results_first_submitted>
  <results_first_submitted_qc>April 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 4, 2021</results_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>zits</keyword>
  <keyword>pimples</keyword>
  <keyword>blackheads</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 6, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT03717506/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Test Product</title>
          <description>GDC 268 Lotion applied topically as directed.&#xD;
GDC 268 Lotion: GDC 268 is a topical lotion</description>
        </group>
        <group group_id="P2">
          <title>Reference Product</title>
          <description>Clindamycin Phosphate Lotion, 1% applied topically as directed.&#xD;
Clindamycin Phosphate Lotion 1%: Clindamycin Phosphate Lotion is an FDA-approved drug product</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>GDC Vehicle lotion applied topically as directed.&#xD;
GDC Vehicle Lotion: GDC Vehicle Lotion contains 0.0% of active drug and is matched to the other two active test drugs</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="496"/>
                <participants group_id="P2" count="491"/>
                <participants group_id="P3" count="249"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="447"/>
                <participants group_id="P2" count="441"/>
                <participants group_id="P3" count="222"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline population includes the Safety and mITT populations, defined as all randomized subjects who applied at least one dose of the test article.</population>
      <group_list>
        <group group_id="B1">
          <title>Test Product</title>
          <description>GDC 268 Lotion applied topically as directed.&#xD;
GDC 268 Lotion: GDC 268 is a topical lotion</description>
        </group>
        <group group_id="B2">
          <title>Reference Product</title>
          <description>Clindamycin Phosphate Lotion, 1% applied topically as directed.&#xD;
Clindamycin Phosphate Lotion 1%: Clindamycin Phosphate Lotion is an FDA-approved drug product</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>GDC Vehicle lotion applied topically as directed.&#xD;
GDC Vehicle Lotion: GDC Vehicle Lotion contains 0.0% of active drug and is matched to the other two active test drugs</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="496"/>
            <count group_id="B2" value="491"/>
            <count group_id="B3" value="249"/>
            <count group_id="B4" value="1236"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.5" spread="6.4"/>
                    <measurement group_id="B2" value="19.3" spread="6.0"/>
                    <measurement group_id="B3" value="19.0" spread="5.1"/>
                    <measurement group_id="B4" value="19.3" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="287"/>
                    <measurement group_id="B2" value="287"/>
                    <measurement group_id="B3" value="151"/>
                    <measurement group_id="B4" value="725"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="209"/>
                    <measurement group_id="B2" value="204"/>
                    <measurement group_id="B3" value="98"/>
                    <measurement group_id="B4" value="511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="216"/>
                    <measurement group_id="B2" value="204"/>
                    <measurement group_id="B3" value="108"/>
                    <measurement group_id="B4" value="528"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="280"/>
                    <measurement group_id="B2" value="287"/>
                    <measurement group_id="B3" value="141"/>
                    <measurement group_id="B4" value="708"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Other category includes subjects that identified with more than one race.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="119"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="287"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="346"/>
                    <measurement group_id="B2" value="350"/>
                    <measurement group_id="B3" value="181"/>
                    <measurement group_id="B4" value="877"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other (multiple)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Investigator's Global Assessment</title>
          <description>To be eligible for study participation, subjects required a clinical diagnosis of mild to severe facial acne vulgaris defined as Grade 2, 3, or 4 on the IGA at Baseline. The IGA (Investigator's Global Assessment) Scale is measured using a five-point scale from 0=Clear to 4=Severe.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>2-Mild</title>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="321"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3-Moderate</title>
                  <measurement_list>
                    <measurement group_id="B1" value="332"/>
                    <measurement group_id="B2" value="319"/>
                    <measurement group_id="B3" value="172"/>
                    <measurement group_id="B4" value="823"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4-Severe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Non-Inflammatory Lesions</title>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.9" spread="20.41"/>
                    <measurement group_id="B2" value="44.9" spread="19.31"/>
                    <measurement group_id="B3" value="45.5" spread="19.42"/>
                    <measurement group_id="B4" value="45.0" spread="19.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Inflammatory Lesions</title>
          <units>Lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.3" spread="8.74"/>
                    <measurement group_id="B2" value="28.4" spread="9.55"/>
                    <measurement group_id="B3" value="27.7" spread="8.64"/>
                    <measurement group_id="B4" value="28.2" spread="9.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Change in the Number of Inflamed Lesions</title>
        <description>Percent Change from Baseline to Week 12 in inflammatory lesion counts (Papules/Pustules).</description>
        <time_frame>12 weeks</time_frame>
        <population>Analysis population is the per-protocol population defined as all subjects in the modified Intent-to-treat (mITT) population who met the following criteria: 1) Met all I/E criteria; 2) No evidence of material dosing noncompliance, 3) Completed the primary endpoint evaluation at Week 12 within the designated visit window (Day 85 ± 6 days), 4) Had no protocol violations that would affect the treatment evaluation, and 5) Did not use any prohibited medications.</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product</title>
            <description>GDC 268 Lotion applied topically as directed.&#xD;
GDC 268 Lotion: GDC 268 is a topical lotion</description>
          </group>
          <group group_id="O2">
            <title>Reference Product</title>
            <description>Clindamycin Phosphate Lotion, 1% applied topically as directed.&#xD;
Clindamycin Phosphate Lotion 1%: Clindamycin Phosphate Lotion is an FDA-approved drug product</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>GDC Vehicle lotion applied topically as directed.&#xD;
GDC Vehicle Lotion: GDC Vehicle Lotion contains 0.0% of active drug and is matched to the other two active test drugs</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change in the Number of Inflamed Lesions</title>
          <description>Percent Change from Baseline to Week 12 in inflammatory lesion counts (Papules/Pustules).</description>
          <population>Analysis population is the per-protocol population defined as all subjects in the modified Intent-to-treat (mITT) population who met the following criteria: 1) Met all I/E criteria; 2) No evidence of material dosing noncompliance, 3) Completed the primary endpoint evaluation at Week 12 within the designated visit window (Day 85 ± 6 days), 4) Had no protocol violations that would affect the treatment evaluation, and 5) Did not use any prohibited medications.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="382"/>
                <count group_id="O2" value="389"/>
                <count group_id="O3" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.4" spread="36.10"/>
                    <measurement group_id="O2" value="-40.0" spread="36.83"/>
                    <measurement group_id="O3" value="-35.1" spread="35.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Change in the Non-inflammatory Lesion Counts</title>
        <description>Percent Change (i.e., reduction) from Baseline to Week 12 in non-inflammatory (open and closed comedones) lesion counts.</description>
        <time_frame>12 weeks</time_frame>
        <population>Data based on the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product</title>
            <description>GDC 268 Lotion applied topically as directed.&#xD;
GDC 268 Lotion: GDC 268 is a topical lotion</description>
          </group>
          <group group_id="O2">
            <title>Reference Product</title>
            <description>Clindamycin Phosphate Lotion, 1% applied topically as directed.&#xD;
Clindamycin Phosphate Lotion 1%: Clindamycin Phosphate Lotion is an FDA-approved drug product</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>GDC Vehicle lotion applied topically as directed.&#xD;
GDC Vehicle Lotion: GDC Vehicle Lotion contains 0.0% of active drug and is matched to the other two active test drugs</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change in the Non-inflammatory Lesion Counts</title>
          <description>Percent Change (i.e., reduction) from Baseline to Week 12 in non-inflammatory (open and closed comedones) lesion counts.</description>
          <population>Data based on the per-protocol population.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="382"/>
                <count group_id="O2" value="389"/>
                <count group_id="O3" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-52.7" spread="33.98"/>
                    <measurement group_id="O2" value="-54.3" spread="34.44"/>
                    <measurement group_id="O3" value="-43.0" spread="39.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Subjects With a Clinical Response (IGA) of &quot;Success&quot; at Week 12</title>
        <description>Investigator's Global Assessment, IGA. Overall severity of acne was assessed using a five-point scale from 0=Clear to 4=Severe. Subjects must have had an IGA score of 2 (mild), 3 (moderate), or 4 (severe) at Baseline. Success is defined as an IGA score at week 12 that is at least 2 grades less than the baseline assessment.</description>
        <time_frame>12 weeks</time_frame>
        <population>Based on the per-protocol population.</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product</title>
            <description>GDC 268 Lotion applied topically as directed.&#xD;
GDC 268 Lotion: GDC 268 is a topical lotion</description>
          </group>
          <group group_id="O2">
            <title>Reference Product</title>
            <description>Clindamycin Phosphate Lotion, 1% applied topically as directed.&#xD;
Clindamycin Phosphate Lotion 1%: Clindamycin Phosphate Lotion is an FDA-approved drug product</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>GDC Vehicle lotion applied topically as directed.&#xD;
GDC Vehicle Lotion: GDC Vehicle Lotion contains 0.0% of active drug and is matched to the other two active test drugs</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Subjects With a Clinical Response (IGA) of &quot;Success&quot; at Week 12</title>
          <description>Investigator's Global Assessment, IGA. Overall severity of acne was assessed using a five-point scale from 0=Clear to 4=Severe. Subjects must have had an IGA score of 2 (mild), 3 (moderate), or 4 (severe) at Baseline. Success is defined as an IGA score at week 12 that is at least 2 grades less than the baseline assessment.</description>
          <population>Based on the per-protocol population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="382"/>
                <count group_id="O2" value="389"/>
                <count group_id="O3" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence of Adverse Events</title>
        <description>Adverse Events (AEs) will be assessed by the investigator and the incidence (severity and causality) of any local and systemic AEs will be reported by number and percentage.</description>
        <time_frame>Day 1 through Day 85</time_frame>
        <population>Based on the Safety population defined as all subjects randomized and applied at least one dose.</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product</title>
            <description>GDC 268 Lotion applied topically as directed.&#xD;
GDC 268 Lotion: GDC 268 is a topical lotion</description>
          </group>
          <group group_id="O2">
            <title>Reference Product</title>
            <description>Clindamycin Phosphate Lotion, 1% applied topically as directed.&#xD;
Clindamycin Phosphate Lotion 1%: Clindamycin Phosphate Lotion is an FDA-approved drug product</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>GDC Vehicle lotion applied topically as directed.&#xD;
GDC Vehicle Lotion: GDC Vehicle Lotion contains 0.0% of active drug and is matched to the other two active test drugs</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events</title>
          <description>Adverse Events (AEs) will be assessed by the investigator and the incidence (severity and causality) of any local and systemic AEs will be reported by number and percentage.</description>
          <population>Based on the Safety population defined as all subjects randomized and applied at least one dose.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="496"/>
                <count group_id="O2" value="491"/>
                <count group_id="O3" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Test Product</title>
          <description>GDC 268 Lotion applied topically as directed.&#xD;
GDC 268 Lotion: GDC 268 is a topical lotion</description>
        </group>
        <group group_id="E2">
          <title>Reference Product</title>
          <description>Clindamycin Phosphate Lotion, 1% applied topically as directed.&#xD;
Clindamycin Phosphate Lotion 1%: Clindamycin Phosphate Lotion is an FDA-approved drug</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>GDC Vehicle lotion applied topically as directed.&#xD;
GDC Vehicle Lotion: GDC Vehicle Lotion contains 0.0% of active drug and is matched to the other two active test drugs</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="496"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="491"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="249"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor has first right to publish pooled study data. In the event that such manuscript has not been submitted for publication within 18 months from study completion/termination at all participating sites, the PI shall have the right to single center publications provided they submit any data for presentation, oral or written, to the Sponsor for review 60 days prior to public disclosure. The PI may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gage Development Clinical Trials</name_or_title>
      <organization>Gage Development Company</organization>
      <phone>1-847-999-0600</phone>
      <email>clinicalinfo@capstonedevservices.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

